Moore 2004.

Methods	Randomised Phase III trial
Participants	280 women with squamous cell Stage IVb, recurrent or persistent cervical cancer. No previous chemotherapy allowed
Interventions	Arm 1: cisplatin 50 mg/m2 iv d1 q21 Arm 2: cisplatin 50 mg/m2 iv d1 and paclitaxel 135 mg/m2 iv d1 q21
Outcomes	Response rates OS PFS Toxicity (WHO)
Notes	16 ineligible patients (7 non‐squamous histology, 1 incorrect stage, 8 inadequate pathology). A further 5 patients did not receive chemotherapy, but were included in the ITT analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	With equal probability block design balancing sequences of assigned arms within institutions
Allocation concealment (selection bias)	Low risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Low risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	16 ineligible patients A further 5 patients did not receive chemotherapy, but were included in the ITT analysis
Selective reporting (reporting bias)	Low risk	Published report included all pre‐specified outcomes
Other bias	Low risk	No hint at any other possible biases